Loading patent…
AssigneeBrown University Research Foundation
InventorsJustin R. Fallon, Beth A. McKechnie, Michael Rafii, Hilliary Creely, Mark A. Bowe, Alison R. Amenta, Mary Lynn Mercado, Hiroki Hagiwara
Estimating the term…
The invention provides compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, due, e.g., to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. Example of diseases include muscular dystrophies, such as Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, neuromuscular disorders and neurological disorders.
A method for stabilizing dystrophin-associated protein complexes (DAPCs) on the surface of a cell, comprising contacting the cell with an effective amount of a biglycan therapeutic, such that the DAPCs are stabilized, wherein the biglycan therapeutic is a polypeptide comprising a biglycan amino acid sequence which is at least about 90% identical to amino acids 38-365 of SEQ ID NO:
Dependencies are inferred from the claim text.